)
Visual
test
Aytu Biopharma
Aytu Biopharma (AYTU) investor relations material
Aytu Biopharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary3 Feb, 2026
Executive summary
Successfully launched Exxua, the first FDA-approved 5-HT1A agonist for MDD, with strong early prescriber and patient interest, shifting commercial focus to CNS therapeutics and away from legacy and pediatric portfolios.
Over 100 physicians in 27 states prescribed Exxua within the first 30 days, with positive early patient feedback on tolerability and satisfaction.
Completed divestiture of Consumer Health business in Q1 FY2025; now operates as a single segment focused on prescription pharmaceuticals.
Entered international agreements to commercialize ADHD products in Israel, the Palestinian Authority, and Canada.
ADHD and pediatric portfolios remain stable, with ADHD net revenue at $13.2M and pediatric net revenue at $1.7M for the quarter.
Financial highlights
Net revenue for the quarter was $15.2M, down from $16.2M year-over-year, mainly due to a shift in marketing focus to Exxua and generic competition in ADHD.
Gross profit was $9.6M (63% margin), down from $10.8M (66%) year-over-year, impacted by a $600K inventory write-down and transition expenses.
Net loss was $10.6M (or $1.05 per share), compared to net income of $0.8M (or $0.13 per share) in the prior year, primarily due to an $8.2M derivative warrant liability loss.
Adjusted EBITDA was -$0.8M, compared to $1.3M in the prior year, reflecting Exxua launch investments.
Cash and cash equivalents stood at $30M as of December 31, 2025.
Outlook and guidance
Exxua launch investments reduced from $10M to under $8M, with $3M as one-time costs.
Management expects Exxua to be a major growth catalyst in the $22B US MDD market, with a focus on accelerating commercial growth and achieving positive operating cash flows.
Breakeven projected at $17.3M net revenue per quarter; cash breakeven at $16.6M per quarter.
OpEx expected to be $4–$5M in the March quarter, normalizing to $11.6M per quarter by fiscal year-end.
Ongoing assessment of strategic transactions, partnerships, and business combinations.
How does RxConnect impact EXXUA's early net revenue?
ADHD erosion: Why not typical vs. generics?
What triggers EXXUA sales force expansion?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit hit ₹21,028.15 crore, driven by robust growth and strategic divestments. - 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next Aytu Biopharma earnings date
Q3 202613 May, 2026
Aytu Biopharma
Next Aytu Biopharma earnings date
Q3 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aytu Biopharma Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare and pediatric-onset disorders. The company’s portfolio includes prescription therapeutics and consumer health products targeting genetic, neurological, and respiratory conditions. It operates through research, licensing, and marketing of branded pharmaceuticals. Aytu Biopharma Inc is headquartered in Englewood, Colorado, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage